Publications by authors named "Siba Kallab"
Article Synopsis
- Ethylene glycol (EG) can lead to serious health issues like metabolic acidemia, neurotoxicity, and acute kidney injury, and historically treatments have included supportive care, antidotes like ethanol or fomepizole, and extracorporeal treatments (ECTRs) like hemodialysis.
- Recent systematic reviews analyzed the effectiveness of ECTRs in treating EG toxicity, showing that while EG is generally dialyzable, mortality rates varied based on glycolate concentrations, with lower rates seen in certain patient subgroups.
- The EXTRIP workgroup provided recommendations for ECTR use alongside supportive care, suggesting it may be beneficial under specific conditions related to EG or glycolate concentrations and severe clinical features, although the quality of
Background: Hemodialysis patients with COVID-19 have been reported to be at higher risk for death than the general population. Several prognostic factors have been identified in the studies from Asian, European or American countries. This is the first national Lebanese study assessing the factors associated with SARS-CoV-2 mortality in hemodialysis patients.
View Article and Find Full Text PDFObjectives: Few data regarding viral replication in patients receiving belatacept are available. The aim of this single-center study was to compare the incidence of viral infections (cytomegalovirus, Epstein Barr virus, BK virus, and JC virus), in 62 de novo kidney transplant patients enrolled in the BENEFIT studies, receiving either belatacept (n=42) or cyclosporine (n=20).
Materials And Methods: By means of polymerase chain reaction, belatacept-treated patients were tested for cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections monthly for 36 months, monthly for the first 6 months, and then quarterly for 36 months in cyclosporine-treated patients.
Background And Aim: Liver transplantation remains the best option for treating type-1 hepatorenal syndrome (HRS1). The aim of this retrospective study was to determine whether the molecular adsorbent recirculation system (MARS) can improve renal function in HRS1 patients.
Methods: Thirty-two patients with chronic liver disease and HRS1 were treated by MARS sessions which were performed every other day.